Tesamorelin + Ipamorelin Blend
Dosage25mg
Rp 2.990.000per vial
Cold-chain delivery to your door around Bali. Pens and bacteriostatic water available, just ask.
- Class
- Growth hormone secretagogue blend (GHRH analogue + ghrelin-receptor agonist)
- Half-life
- Both short. Tesamorelin about 26 to 38 minutes, ipamorelin about 2 hours
Also known as Tesa/Ipa, Tesamorelin + Ipamorelin blend
Tested in mid-stage human trials. Promising, but not yet confirmed in large trials.
Graded conservatively because the BLEND has no trial behind it. The components are very unevenly evidenced. Tesamorelin is FDA-approved for one narrow indication and carries pivotal Phase 3 RCT data (Falutz NEJM 2007, n=412; pooled n~806) plus a positive 12-month liver-fat trial. Ipamorelin has no approval anywhere and its only completed human efficacy trial, a Phase 2 in postoperative ileus, missed its primary endpoint. The two have never been given together in any published human or animal study. The synergy rationale is strong class-level human pharmacology using older GHRPs, not ipamorelin specifically, and it concerns growth hormone output rather than any clinical outcome.
About this peptide
This blend puts the two halves of the growth hormone axis in one pen. Tesamorelin acts on the GHRH receptor and raises the size of the body's own growth hormone pulse. Ipamorelin acts on a different receptor entirely, the ghrelin receptor, which both adds to the pulse and lifts the brake (somatostatin) that would otherwise limit it. Because they work through two separate pathways, the combined release is larger than adding the two together would suggest. That synergy is well-established pharmacology for this class of pairing. The specific pairing of these two compounds has not itself been studied, so what is known comes from each one separately. Supplied as a freeze-dried powder for research use.
What it does
Researched for deep abdominal fat, body recomposition and growth hormone output. Tesamorelin is the component with the specific, well-evidenced fat result: in its pivotal trial it cut visceral (deep abdominal) fat by about 15% while leaving fat under the skin alone, so it changes where fat sits rather than moving the scale much. Ipamorelin is added as the pulse amplifier, chosen over older peptides in its class because it does the job without raising cortisol or prolactin.
What to expect
Week 1
a growth hormone pulse after each injection, within about 15 to 40 minutes for the ipamorelin component and over 1 to 2 hours for tesamorelin; IGF-1 (a growth factor) starting to rise; mild injection site reactions; possible puffiness or 'puffy hands'; drowsiness after a pre-bed shot is common
Weeks 2-4
IGF-1 reaching a plateau by around two weeks; joint stiffness possible; body weight generally unchanged, since this shifts where fat sits rather than shedding weight
Weeks 4-12
deep abdominal fat reduction starting to show on imaging in the tesamorelin trials; triglycerides and non-HDL cholesterol improving in responders; fat under the skin largely unchanged
Long term
in tesamorelin's trials the deep-abdominal-fat effect peaked around 26 weeks and held through 52 weeks with continued dosing. It reverses on stopping: the fat comes back, so the benefit lasts as long as the dosing does. Multi-year safety is untested, and there is no long-term data at all for the two used together
A rough guide drawn from research and community reports. Individual results vary and nothing here is a promise.
Reported effects
Reported benefits
Side effects & cautions
Key points
Suits people researching deep abdominal fat and the growth hormone axis who want the strongest-evidenced GHRH peptide rather than the lighter blends. It is a natural step up for anyone who found a CJC-1295 based blend too mild, since tesamorelin is the better-documented half. Best for those comfortable that the evidence sits with each compound separately, that tesamorelin's trial data come from one specific patient population, and that the pairing itself rests on mechanism rather than a trial. Like other growth hormone peptides, both are on anti-doping lists.
Two receptors, two different signalling systems. Tesamorelin is a stabilised full-length GHRH analogue: it binds the GHRH receptor on the pituitary and raises pulse amplitude, and a chemical modification protects it from the enzyme that breaks down natural GHRH, stretching its working life to roughly half an hour. Ipamorelin binds the ghrelin receptor instead, which drives the pulse directly, recruits the body's own GHRH, and acts against somatostatin, the signal that normally shuts growth hormone release down. Given alone, each one runs into the limit the other removes. Human studies of this receptor pairing (Bowers and colleagues, 1990 onward) showed the combination produces more growth hormone than the two added together. Those studies used older peptides rather than ipamorelin specifically.
The reported effects are those of the growth hormone class generally, and most are mild and dose related: fluid retention and puffiness, joint aches, muscle aches, injection site reactions, and tingling or carpal-tunnel-type symptoms in the hands, which are driven by the fluid retention. Growth hormone works against insulin, so blood sugar is the thing to watch on long runs, though tesamorelin's trials found no meaningful change over 12 weeks in people with type 2 diabetes and no glycaemic difference in the pivotal trial. The sensible ceiling is keeping IGF-1 inside the normal range for your age rather than pushing above it. Long-term data for the two used together does not exist. Purity matters, and a Certificate of Analysis is shared where our supplier provides one.
Supplied freeze-dried. Reconstitute with bacteriostatic water, then refrigerate at 2-8°C and keep it out of the light. Our 25 mg pen holds 20 mg tesamorelin plus 5 mg ipamorelin; reconstituted to 2 ml that gives 12.5 mg/ml, where 10 clicks delivers 1 mg tesamorelin plus 250 mcg ipamorelin. The ratio is fixed, so the two always rise and fall together. Dose subcutaneously, fasted, and pre-bed is the usual slot. We can reconstitute to spec for you as a paid service, or fill a pen.
- Blood pressure
- No significant effect reported
- Heart rate
- No significant effect reported
- Blood sugar
- No significant change in trials; long-term untested
- Lipids / cholesterol
- Triglyceride and non-HDL reduction
- IGF-1
- IGF-1 (a growth factor) elevation, about 81% in the pivotal trial
What studies and users commonly report happening to these markers. Research context only, not medical advice.
Questions about Tesamorelin + Ipamorelin Blend
No. No human or animal study has given tesamorelin and ipamorelin together, and no clinical trial has been registered for the pairing. What is known comes from each compound on its own, plus decades of human work on pairing a GHRH peptide with a ghrelin-receptor peptide in general. We would rather say that plainly than imply otherwise.
Because they work on two different receptors through two different signalling systems, and each one removes the limit the other runs into. Tesamorelin raises the pulse but is capped by somatostatin; ipamorelin lifts that brake and adds to the pulse. Human studies of this receptor pairing consistently show more growth hormone released than the two added together. That part is solid pharmacology. What has not been shown is that it translates into better body-composition results than tesamorelin alone.
The ipamorelin half is the same idea. The GHRH half is the upgrade: tesamorelin is full-length, FDA-approved for one specific indication, and is the only peptide in this class with a large placebo-controlled trial showing a specific deep abdominal fat result. CJC-1295 has no approval and no comparable outcome data.
No. In the trials the deep abdominal fat reduction held for as long as dosing continued and came back after stopping. Treat it as something you maintain, not a course you finish.
Cycling is a community habit rather than an evidence-based requirement, and for tesamorelin it is arguably counterproductive: the trials dosed continuously for 6 to 12 months without the effect fading. The ipamorelin side is where the receptor-desensitisation argument for taking breaks comes from.
IGF-1 first, at baseline and every 3 to 6 months, keeping it inside the range for your age. Fasting glucose and HbA1c for the insulin side. And prolactin and cortisol as a useful check that the ipamorelin is behaving selectively, since neither should rise if it is.
Yes. Both compounds are prohibited in sport at all times as growth hormone secretagogues, and validated tests exist. There is no therapeutic use exemption.
Evidence
- Falutz et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV, pivotal Phase 3 RCT, NEJM 2007
- Stanley et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV, randomised trial, Lancet HIV 2019
- Raun et al. Ipamorelin, the first selective growth hormone secretagogue, Eur J Endocrinol 1998
- Gobburu et al. Pharmacokinetic-pharmacodynamic modelling of ipamorelin in healthy volunteers, Pharm Res 1999
- Beck et al. Ipamorelin for postoperative ileus, randomised Phase 2 (missed primary endpoint), Int J Colorectal Dis 2014
Sourcing
Sourced carefully from vetted suppliers. Where a Certificate of Analysis is available we share it on request, and we'll always tell you what we have for your batch.
For Research Use Only
Sold strictly for laboratory and research purposes. Not for human or veterinary use, not a medicine, and not for diagnostic or therapeutic application.
GH Secretagogues
CJC-1295 no DAC + Ipamorelin Blend
10mg
Tesamorelin
10mg
Ipamorelin
5mg